Abstract 2142P
Background
The improvement in cancer survival, allows for higher ICU admission ratios. A pilot program in our center instituted weekly meetings between ICU and Oncology aimed at determining the appropriate level of care for patients admitted in Oncology. Objective: establish which factors predict decision-making regarding the level of care and admission to the ICU and benefit of intensive care.
Methods
Single-center prospective observational study. Recruitment between September-2021 and July-2022. Statistical analysis: descriptive study, multivariate logistic regression for decision of admission in ICU. We performed a second subsequent analysis with the paired propensity score matching technique. Survival analysis: Kaplan-Meier (KM) curves and log-Rank test. Significance level: p ≤ 0.05.
Results
411 patients. 60.3% male; median age: 64 years. Most prevalent tumor: lung (26.3%). Stage IV: 72.5%. The most common reason for admission in Oncology: infectious pathology (33.8%). 54.7% were considered ICU candidates, while only 17 patients (4.1%) finally required intensive care. In a multivariate logistic regression model, ECOG 0-1 (OR 2.7; IC95%: 1.6-4.5), absence of peritoneal carcinomatosis (OR 4.5; IC95%: 2.0-9.9), and intentionality of treatment (adjuvant, neoadjuvant or first-line) (OR 5.4; IC 95%: 3.1-9.5) predicted decision of admission to the ICU. Age > 65 years (OR 0.35; IC 95%: 0.2-0.6) and poor symptom control as cause of admission in Oncology (OR 0.16; 95%: 0.03-0.93) were negative factors for ICU admission. By means of paired propensity analysis (Nearest-neighbor model), the sample was reduced to 172 patients and there was only statistical significance in the univariate analysis for intentionality of treatment and for treatment with immunotherapy (IT). After a median follow-up of 4 months, median survival was significantly different (p< 0.05) for patients who were not ICU candidates (2.5 months), patients who were admitted to the ICU (10 months) and patients who were ICU candidates but did not require admission (12.5 months).
Conclusions
Multidisciplinary decision-making may contribute to individualize the level of intensive care for Oncology patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
F. Ayala de la Pena
Funding
Has not received any funding.
Disclosure
M. Sanchez Canovas: Financial Interests, Advisory Board: Leo Pharma, Sanofi, Lundbeck, Angelini. All other authors have declared no conflicts of interest.
Resources from the same session
2140P - Short-term quality-of-life after metastases-directed SBRT: Results of the prospective ESTRO & EORTC OligoCare cohort
Presenter: Daniela Greto
Session: Poster session 07
2141P - Symptom burden and health-related quality of life (HRQoL) in platinum-resistant or -refractory ovarian cancer (PROC): A systematic literature review (SLR)
Presenter: Nikhila Indukuri
Session: Poster session 07
2143P - Mortality within 30 days after last dose of intravenous systemic anti-cancer therapy: Single-center, one-year, retrospective analysis
Presenter: Osman Sutcuoglu
Session: Poster session 07
2144P - The PRognostic Oncologic Plantology (PROP) website tool predicts 30-day mortality in hospitalized cancer patients on treatment
Presenter: Oriol Mirallas
Session: Poster session 07
2145P - Thromboembolic disease associated with cyclin-dependent kinase inhibitors in patients with breast cancer
Presenter: Javier López Robles
Session: Poster session 07
2146P - Cancer-associated thrombosis clinic: Experience of the Medical Oncology Department of a hospital in Spain
Presenter: Laura Ortega Morán
Session: Poster session 07
2147P - Thrombotic recurrence and bleeding complications in non-small cell lung carcinoma (NSCLC) patients with venous thromboembolism (VTE)
Presenter: Irene Gonzalez Caraballo
Session: Poster session 07
2148P - Venous thromboembolism (VTE) in patients with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitors
Presenter: Lorenzo Gervaso
Session: Poster session 07
2149P - Catheter-related thrombosis in cancer patients: Data from the registry of thrombosis and neoplasia of SEOM (TESEO)
Presenter: Francisco Pelegrín Mateo
Session: Poster session 07
2150P - Clinical and molecular characterisation of cancer-associated venous thromboembolism (VTE)
Presenter: Pau Mascaró Baselga
Session: Poster session 07